Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02181738 · ClinicalTrials.gov registry record · Phase 2
Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 294
- Enrollment target
NCT02181738: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT02181738 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 294 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (121% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02181738, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 294 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B \& C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma participants.
Primary Outcome
ORR is the percent of participants achieving either a complete remission (CR) or partial remission (PR) according to the 2007 IWG criteria. Analyses of efficacy endpoints were performed separately for each cohort, according to IWG 2007. For cohort A and B, if the bone marrow was involved by lymphoma before treatment, the infiltrate must have cleared on repeat bone marrow biopsy. For cohort C, no evidence of FDG-avid disease in bone marrow was required in all participants in lieu of bone marrow a
Interventions
- DRUG Doxorubicin
- DRUG Nivolumab
- DRUG Dacarbazine
- DRUG Vinblastine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2014-08-12 |
| Est. Completion | 2022-12-27 |
| Phase | Phase 2 |
What the finished NCT02181738 record still lists
NCT02181738 is an interventional study that assigns participants to a tested intervention. The registered 294 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (121% higher).
The record links to 0 conditions, and to 4 interventions - of which Doxorubicin is the first listed.
NCT02181738 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02181738 about?
NCT02181738 is a clinical study titled "Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)". The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B \& C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma participants.
What is the current status of trial NCT02181738?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 294 participants. The study started on 2014-08-12. Estimated completion is 2022-12-27.
What interventions are being tested in trial NCT02181738?
The interventions under investigation include: Doxorubicin (DRUG), Nivolumab (DRUG), Dacarbazine (DRUG), Vinblastine (DRUG).
Who is sponsoring clinical trial NCT02181738?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02181738's enrollment target sits among peer trials
294 190th of 2000 higher than 1,810 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05775159 · 294 participants · Phase 2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
- NCT06262113 · 294 participants · NA
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
- NCT06338865 · 294 participants · NA
Short Title: Standard vs. Lower Pressure Pneumoperitoneum
- NCT06395467 · 294 participants · NA
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI